



# COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

## DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board  
Thursday, September 12, 2019, 2:00pm  
DMAS 7B Conference Room  
Agenda

1. **Call to Order and Introductions** – Chethan Bachireddy, MD, Chief Clinical Innovation Officer, Chief Medical Officer, Chair
2. **Minutes** - Approval of Minutes from June 13, 2019 meeting
3. **RetroDUR Criteria Estimates**
4. **New Drugs - Grid**
  - a. Balversa™ (erdafitinib)
  - b. Dovato® (dolutegravir and lamivudine)
  - c. Egaten™ (triclabendazole)
  - d. Nucala® (mepolizumab) Prefilled Autoinjector and Syringe
  - e. Piqray® (alpelisib)
  - f. Vyndaqel® (tafamidis meglumine)
  - g. Drug Updates: New Generics; New Dosage Form/ Strength; PDL-Eligible; Physician Administered Drugs.
5. **Specialty Drugs**
  - a. Children with Peanut Allergy
  - b. MRx Pipeline



# COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

## DRUG UTILIZATION REVIEW PROGRAM

### 6. Topics for Discussion

- a. Antihemophilic Drug Factors
- b. Synagis
- c. Concurrent Use of Opioids and Benzodiazepines
- d. Acetaminophen Doses Greater than 4 Grams
- e. DUR Quarterly Newsletter

### 7. Surveillance

- a. Analysis of Compounded Medications
- b. Pediatric and Adult Opioid Utilization
- c. Antipsychotic Duplication
- d. Opioid Use with Risk Factors and No Naloxone

### 8. Reports

- a. ProDUR
- b. RetroDUR
- c. Utilization Analysis

### 9. Adjournment